Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort.
Although nonalcoholic fatty liver disease (NAFLD) is frequent in obesity, the metabolic determinants of advanced liver disease remain unclear. Adipokines reflect inflammation and insulin resistance associated with obesity and may identify advanced NAFLD. At the time of obesity surgery, 142 consecutive patients underwent liver biopsy and had their preoperative demographic and clinical data obtained. Liver histology was scored by the NAFLD activity score, and patients subdivided into four groups. Concentrations of retinol-binding protein 4 (RBP4), adiponectin, tumor necrosis factor-alpha (TNF-alpha), and leptin were determined approximately 1 week prior to surgery and results were related to liver histology. The prevalence of no NAFLD was 30%, simple steatosis 23%, borderline nonalcoholic steatohepatitis (NASH) 28%, and definitive NASH 18%. Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS) prevalence were 39 and 75%, respectively, and did not differ across the four histological groups (P = NS). Triglyceride (TG) and alanine transaminase (ALT) levels, strongly associated with advanced stages of NAFLD and NASH (P = 0.04). TG levels >150 mg/dl, increased the likelihood of NASH 3.4-fold, whereas high-density lipoprotein (HDL) levels predicted no NAFLD (P < 0.01). Concentrations of TNF-alpha, leptin, and RBP4 did not differ among histological groups and thus did not identify NASH; however, there was a trend for adiponectin to be lower in NASH vs. no NAFLD (P = 0.061). In summary, both TG and ALT levels assist in identification of NASH in an obesity surgery cohort. These findings underscore the importance of fatty acid delivery mechanisms to NASH development in severely obese individuals.
Kashyap
Sangeeta R
SR
Endocrinology Institute, Cleveland Clinic, Cleveland, Ohio, USA. kashyas@ccf.org
Diab
Dima L
DL
Baker
Allison R
AR
Yerian
Lisa
L
Bajaj
Harpreet
H
Gray-McGuire
Courtney
C
Schauer
Philip R
PR
Gupta
Manjula
M
Feldstein
Ariel E
AE
Hazen
Stanley L
SL
Stein
Catherine M
CM
D054392:Adipokines / Q000097:blood*; D052242:Adiponectin / Q000097:blood; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D050110:Bariatric Surgery / Q000379:methods; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005234:Fatty Liver / Q000097:blood / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D010535:Laparoscopy; D020738:Leptin / Q000097:blood; D008099:Liver / Q000201:enzymology / Q000473:pathology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000601:surgery; D011237:Predictive Value of Tests; D054839:Retinol-Binding Proteins, Plasma / Q000378:metabolism; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D014280:Triglycerides / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
C499918:ADIPOQ protein, human; D054392:Adipokines; D052242:Adiponectin; D015415:Biomarkers; D020738:Leptin; C101326:RBP4 protein, human; D054839:Retinol-Binding Proteins, Plasma; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D000410:Alanine Transaminase